Market Place
Sourcing Support
Nutriband Secure Full Patent for Abuse-Deterrent Transdermal System
31 Oct 2024 //
ACCESSWIRE
Nutriband`s Mosquito Repellent Patch Approved in Costa Rica
17 Oct 2024 //
ACCESSWIRE
Nutriband Licenses Bitrex For Aversa Fentanyl Patch
20 Sep 2024 //
ACCESSWIRE
Nutriband Inc. Authorizes $1M Share Buyback Program
16 Sep 2024 //
ACCESSWIRE
Join Nutriband`s Exclusive Live Investor Webinar and Q&A Session on July 25
19 Jul 2024 //
ACCESSWIRE
Nutriband Receives Trademark Allowance For AVERSA Abuse Deterrent Technology
15 Jul 2024 //
ACCESSWIRE
Nutriband Updates Development Of Aversa Fentanyl Lead Product
20 Jun 2024 //
ACCESSWIRE
Nutriband Q1 Sports Tape Revenue Up 219%, Focus On Kinesiology Tapes
03 Jun 2024 //
ACCESSWIRE
Join Nutriband`s Exclusive Live Investor Webinar and Q&A Session on May 30
21 May 2024 //
ACCESSWIRE
Nutriband Appoints Sergei Glinka To Board Of Directors
16 May 2024 //
ACCESSWIRE
Nutriband Raises $8.4M for Fentanyl Patch to FDA Filing
24 Apr 2024 //
ACCESSWIRE
Nutriband Signs Supplier Deal with Fit for Life Licensee
23 Apr 2024 //
ACCESSWIRE
Nutriband Inc. Announces $8.4M Private Placement
19 Apr 2024 //
ACCESSWIRE
Nutriband Begins Manufacturing for Major Sports Brand Licensee Fit for Life Grp
01 Apr 2024 //
ACCESSWIRE
Nutriband Provides Clinical Overview for Lead Product - AVERSA(R)
27 Mar 2024 //
ACCESSWIRE
Nutriband Announces Data Supporting Need for Safer AD Transdermal Patches
25 Mar 2024 //
ACCESSWIRE
Nutriband’s Aversa(TM) Buprenoprhine May Reach Annual Sales of $70-130 Million
11 Oct 2023 //
ACCESSWIRE
Nutriband Inc. Reports Second Quarter 2023 Financial Results
11 Sep 2023 //
ACCESSWIRE
Nutriband Increases Credit Line to $5 Million USD for AVERSA(TM) Platform
14 Jul 2023 //
ACCESSWIRE
Nutriband Receives Notice of Allowance for U.S. Patent Covering
23 Jun 2023 //
ACCESSWIRE
Nutriband Secures $2 Million Line of Credit Financing Facility
28 Mar 2023 //
ACCESSWIRE
Nutriband Inc. to File for Product Distribution Permit in South America
15 Feb 2023 //
ACCESSWIRE
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference
24 Jan 2023 //
ACCESSWIRE
Nutriband Inc. Will Be the First Company to Dual List on Upstream
30 Dec 2022 //
ACCESSWIRE
Nutriband Approved for Dual Listing on Upstream
14 Dec 2022 //
ACCESSWIRE
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property
01 Dec 2022 //
ACCESSWIRE
Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines
08 Nov 2022 //
ACCESSWIRE
4P Conducts Ph 1b Study for Sorrento on Lymphatic Etanercept Delivery
26 Oct 2022 //
ACCESSWIRE
Nutriband With Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterren
04 Oct 2022 //
ACCESSWIRE
Safe Group Announces Strategic Agreements with Wenzel Spine
03 Oct 2022 //
GLOBENEWSWIRE
Nutriband Inc. Provides Update on Seven-for-Six Forward Stock Split
16 Aug 2022 //
ACCESSWIRE
Nutriband Inc. Details of Seven-for-Six Forward Stock Split
10 Aug 2022 //
ACCESSWIRE
Nutriband Receives Notice of Allowance from the Canadian IPO
01 Aug 2022 //
ACCESSWIRE
Nutriband Inc. Announces Seven-for-Six Forward Stock Split
27 Jul 2022 //
PRESS RELEASE
1.2M Shares of Nutriband Inc. to be Cancelled from Total Outstanding Shares
26 Jul 2022 //
MARKETWATCH
Nutriband Inc. Registers New Company Branch in Ecuador
22 Jul 2022 //
BENZINGA
Nutriband Inc. Successfully Obtains Court Verdict for Recovery of Shares
15 Jul 2022 //
BIGNEWSNETWORK
Nutriband Subsidiary Active Intelligence LLC Registers with FDA
11 May 2022 //
ACCESSWIRE
Nutriband Inc. Reports Revenue Up 56% in Fiscal 2022 to a Record $1.4M
29 Apr 2022 //
PRNEWSWIRE
